Literature DB >> 16340389

Bupropion may improve restless legs syndrome: a report of three cases.

Sung-Wan Kim1, Il-Seon Shin, Jae-Min Kim, Su-Jin Yang, Hee-Young Shin, Jin-Sang Yoon.   

Abstract

Restless legs syndrome (RLS) is a common disorder for which agents that enhance dopaminergic activity, including dopamine agonists and levodopa, are the treatment of choice. However, long-term use of dopaminergic drugs can cause unwanted effects such as rebound, tolerance, and augmentation. Bupropion, an inhibitor of dopamine and noradrenalin reuptake, is an antidepressant that modulates dopaminergic systems. The authors report that a low dose of bupropion rapidly and completely ameliorated RLS symptoms in 3 depressed patients within a few days of the initiation of treatment. To their knowledge, this is the first report to show that bupropion may be an effective alternative for treating RLS. Consequently, bupropion may be useful for the treatment of patients with both depression and RLS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16340389     DOI: 10.1097/01.wnf.0000194706.61224.29

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  11 in total

1.  Weighing the balance: how analgesics used in chronic pain influence sleep?

Authors:  Miqdad H Bohra; Chhavi Kaushik; Daniel Temple; Sharon A Chung; Colin M Shapiro
Journal:  Br J Pain       Date:  2014-08

Review 2.  [Restless legs syndrome, periodic limb movements, and psychopharmacology].

Authors:  S Cohrs; A Rodenbeck; M Hornyak; D Kunz
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

3.  Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management.

Authors:  Magdolna Hornyak
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

4.  Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder.

Authors:  Young-Min Park; Heon-Jeong Lee; Seung-Gul Kang; Jae-Hyuck Cho; Leen Kim
Journal:  Psychiatry Investig       Date:  2009-11-19       Impact factor: 2.505

Review 5.  Strategies for the treatment of restless legs syndrome.

Authors:  Mark J Buchfuhrer
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

Review 6.  [Depression in restless legs syndrome. Pathogenesis, assessment, and implications for treatment].

Authors:  M Hornyak; H Benes; I Eisensehr; J Haan; J Kassubek; I Peglau; K Stiasny-Kolster; C Trenkwalder
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

7.  The biopsychosocial effects of restless legs syndrome (RLS).

Authors:  Philip M Becker
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

8.  Synthesis, screening and pharmacokinetic evaluation of potential prodrugs of bupropion. Part one: in vitro development.

Authors:  Paul Matthew O'Byrne; Robert Williams; John J Walsh; John F Gilmer
Journal:  Pharmaceuticals (Basel)       Date:  2014-05-14

9.  Part Two: Evaluation of N-methylbupropion as a Potential Bupropion Prodrug.

Authors:  Paul Matthew O'Byrne; Robert Williams; John J Walsh; John F Gilmer
Journal:  Pharmaceuticals (Basel)       Date:  2014-05-28

10.  The effects of two methods of reflexology and stretching exercises on the severity of restless leg syndrome among hemodialysis patients.

Authors:  Nahid Shahgholian; Shahrzad Khojandi Jazi; Jahangir Karimian; Mahboubeh Valiani
Journal:  Iran J Nurs Midwifery Res       Date:  2016 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.